Skip to Main content Skip to Navigation
Journal articles

Intérêt de la MGMT dans les gliomes. [MGMT analysis in gliomas].

Abstract : MGMT status is now regarded as a strong predictive factor of response to standard treatment of newly diagnosed glioblastomas involving temozolomide (TMZ) and radiotherapy. MGMT promoter methylation is also a prognostic factor - independent of treatment - in anaplastic gliomas. The predictive function can be explained by the role of the DNA repair enzyme MGMT, which antagonizes the effects of alkylating agents such as TMZ. MGMT promoter methylation could also reflect a particular molecular phenotype with its own specific prognostic significance. Since MGMT status determination is becoming a crucial biological marker in new clinical glioma trials, and is beginning to be used in day-to-day clinical practice, there is currently a strong need to determine the best technique for MGMT analysis. A French multicenter study has been set up for this purpose.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00587564
Contributor : Hervé de Villemeur <>
Submitted on : Wednesday, April 20, 2011 - 5:42:19 PM
Last modification on : Wednesday, May 16, 2018 - 11:23:34 AM

Identifiers

Citation

Véronique Quillien, Elodie Vauléon, Stephan Saikali, Thierry Lesimple, Abderrahmane Hamlat, et al.. Intérêt de la MGMT dans les gliomes. [MGMT analysis in gliomas].. Bulletin du Cancer, John Libbey Eurotext, 2011, 98 (3), pp.291-303. ⟨10.1684/bdc.2011.1332⟩. ⟨inserm-00587564⟩

Share

Metrics

Record views

267